Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) had its price objective raised by analysts at Truist Financial from $110.00 to $128.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price objective suggests a potential upside of 17.52% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush lifted their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, HC Wainwright increased their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $124.27.
Get Our Latest Analysis on Dianthus Therapeutics
Dianthus Therapeutics Stock Performance
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. On average, analysts predict that Dianthus Therapeutics will post -3.94 EPS for the current fiscal year.
Insider Activity at Dianthus Therapeutics
In other news, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. The trade was a 86.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president owned 31,249 shares in the company, valued at approximately $3,157,086.47. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 253,779 shares of company stock worth $25,931,495. 3.02% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its stake in Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after purchasing an additional 139 shares during the period. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics during the first quarter worth about $32,000. Virtus Investment Advisers LLC boosted its stake in shares of Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after purchasing an additional 416 shares during the period. Royal Bank of Canada boosted its stake in shares of Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after purchasing an additional 542 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Stories
- Five stocks we like better than Dianthus Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
